ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
148.25 USD   +1.65%
06/27EUCOPE Member Spotlight, Q&A with Alnylam
AQ
06/27Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral From Buy
MT
06/15SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $98 From $96, Maintains Market Perform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
146.49(c) 142.2(c) 145.43(c) 145.85(c) 148.25(c) Last
1 198 014 1 716 752 441 019 837 703 568 298 Volume
-0.68% -2.93% +2.27% +0.29% +1.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 089 M - -
Net income 2022 -856 M - -
Net cash position 2022 1 216 M - -
P/E ratio 2022 -21,7x
Yield 2022 -
Sales 2023 1 608 M - -
Net income 2023 -466 M - -
Net cash position 2023 1 283 M - -
P/E ratio 2023 -43,8x
Yield 2023 -
Capitalization 17 911 M 17 911 M -
EV / Sales 2022 15,3x
EV / Sales 2023 10,3x
Nbr of Employees 1 665
Free-Float 99,3%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based... 
More about the company
Ratings of Alnylam Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALNYLAM PHARMACEUTICALS, INC.
06/27EUCOPE Member Spotlight, Q&A with Alnylam
AQ
06/27Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral From Buy
MT
06/15SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $98 From $96, Maintai..
MT
06/14SECTOR UPDATE : Health Care Stocks Finish Above Tuesday's Worst Levels
MT
06/14SECTOR UPDATE : Health Care Stocks Declining in Tuesday Trading
MT
06/14SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Tuesday
MT
06/14TRANSCRIPT : Alnylam Pharmaceuticals, Inc. - Special Call
CI
06/14ALNYLAM PHARMACEUTICALS : Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi T..
PU
06/14ALNYLAM PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/14Alnylam Pharmaceuticals Says FDA Approves Amvuttra to Treat Polyneuropathy Caused by Ra..
MT
06/13Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for..
BU
06/13Alnylam Announces FDA Approval of AMVUTTRA, an RNAi Therapeutic for the Treatment of th..
CI
06/13TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global He..
CI
06/09TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Co..
CI
06/09Alnylam Pharmaceuticals Says Cemdisiran Product Meets Primary Endpoint of Immunoglobuli..
MT
More news
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
06/14MISE À JOUR SECTORIELLE : Les actions du secteur de la santé en baisse dans les échanges d..
06/14MISE À JOUR SECTORIELLE : Les actions du secteur de la santé grimpent avant la cloche de m..
06/14Alnylam Pharmaceuticals déclare que la FDA approuve Amvuttra pour traiter la polyneurop..
06/13Alnylam annonce l'approbation par la FDA d'AMVUTTRA (vutrisiran), un ARNi thérapeutique..
06/09Alnylam annonce des résultats préliminaires positifs de l'étude de phase 2 du Cemdisira..
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 148,25 $
Average target price 204,91 $
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet Chief Executive Officer & Director
Akshay K. Vaishnaw President
Jeffrey V. Poulton Chief Financial Officer & Executive Vice President
Michael W. Bonney Independent Director
Pushkal P. Garg Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-12.58%17 911
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.60%19 031